Ameliorative effect of certolizumab on experimentally induced acute necrotic pancreatitis in rats
dc.authorid | 0000-0002-1835-1082 | en_US |
dc.authorid | 0000-0002-3172-8200 | en_US |
dc.authorid | 0000-0001-9172-0545 | |
dc.contributor.author | Kösekli, Mehmet Ali | |
dc.contributor.author | Herek, Özkan | |
dc.contributor.author | Özmen, Özlem | |
dc.contributor.author | Şahinduran, Sima | |
dc.date.accessioned | 2021-06-23T19:52:14Z | |
dc.date.available | 2021-06-23T19:52:14Z | |
dc.date.issued | 2019 | |
dc.department | BAİBÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü | en_US |
dc.description.abstract | OBJECTIVE: The effects of Certolizumab, a pegylated monoclonal antibody to tumor necrosis factor alpha, on experimentally induced acute pancreatitis (AP) were examined. METHODS: Thirty-six Wistar Albino male rats were randomly divided into four groups. Group I was the control group and no medication administered to this group. Group II was the Certolizumab group, and 100 ml/kg serum physiologic administered into the biliopancreatic duct and a single dose of 10 mu g Certolizumab was simultaneously administered intraperitoneally. Acute pancreatitis was induced with a retrograde injection of 3% Na taurocholate into the common biliopancreatic duct in the study (Group III) and treatment (Groups IV) groups. Rats were sacrificed 72 hours later. Serum amylase, lipase, lactate dehydrogenase activities, along with pancreatic histopathology, were examined. RESULTS: Certolizumab treatment significantly decreased serum amylase, lipase, and LDH levels; histopathologically edema, hemorrhage, parenchymal necrosis, fat necrosis, and infiltration scores; immunohistochemically MDA, MPO, TNF-alpha and Caspase-3 activity. CONCLUSION: The results support the idea that certolizumab might be beneficial for the severity of AP. | en_US |
dc.identifier.doi | 10.1590/1806-9282.65.2.204 | |
dc.identifier.endpage | 210 | en_US |
dc.identifier.issn | 1806-9282 | |
dc.identifier.issue | 2 | en_US |
dc.identifier.pmid | 30892445 | en_US |
dc.identifier.startpage | 204 | en_US |
dc.identifier.uri | https://doi.org/10.1590/1806-9282.65.2.204 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12491/10118 | |
dc.identifier.volume | 65 | en_US |
dc.identifier.wos | WOS:000461474100019 | en_US |
dc.identifier.wosquality | Q4 | en_US |
dc.indekslendigikaynak | Web of Science | en_US |
dc.indekslendigikaynak | PubMed | en_US |
dc.institutionauthor | Kösekli, Mehmet Ali | |
dc.language.iso | en | en_US |
dc.publisher | Assoc Medica Brasileira | en_US |
dc.relation.ispartof | Revista Da Associacao Medica Brasileira | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Pancreatitis, Acute Necrotizing | en_US |
dc.subject | Certolizumab Pegol | en_US |
dc.subject | Rats | en_US |
dc.title | Ameliorative effect of certolizumab on experimentally induced acute necrotic pancreatitis in rats | en_US |
dc.type | Article | en_US |
Dosyalar
Orijinal paket
1 - 1 / 1
Yükleniyor...
- İsim:
- mehmet-ali-kosekli.pdf
- Boyut:
- 254.58 KB
- Biçim:
- Adobe Portable Document Format
- Açıklama:
- Tam Metin/Full Text